首页> European urology> Re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8: The Change in Baseline IMDC Prognostic Category: From the Past, Implications for the Future.

Re: Ian D. Davis, Wanling Xie, Carmel Pezaro, et al. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol 2017;71:970-8: The Change in Baseline IMDC Prognostic Category: From the Past, Implications for the Future.

导出 LinkOut

翻译打印收藏纠错

第一作者： Roberto,Iacovelli

第一单位： Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. Electronic address: roberto.iacovelli@ospedaleuniverona.it.

作者： Roberto,Iacovelli ^[1] ; Walter,Artibani ^[2] ; Giampaolo,Tortora ^[3]

作者单位： Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. Electronic address: roberto.iacovelli@ospedaleuniverona.it. ^[1] Urology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. ^[2] Medical Oncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy. ^[3]

医学主题词癌, 肾细胞(Carcinoma, Renal Cell);人类(Humans);肾肿瘤(Kidney Neoplasms);分子靶向治疗(Molecular Targeted Therapy);肿瘤, 继发原发性(Neoplasms, Second Primary);预后(Prognosis)

DOI 10.1016/j.eururo.2016.12.012

PMID 28043706

发布时间 2018-12-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交